Human prolactin antagonist-angiogenesis inhibitor fusion proteins
AssigneeOncolix, Inc.
InventorWen Y. Chen
Life of this patent
Estimating the term…
Abstract
A novel fusion protein, comprising a receptor-antagonizing domain and an angiogenesis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.
Claims3
A method for treating breast or prostate cancer expressing a prolactin receptor, comprising administering to a patient an effective amount of a protein having a receptor-antagonizing domain and an angiogenesis-inhibiting domain, wherein the angiogenesis-inhibiting domain is endostatin and wherein the receptor-antagonizing domain is a prolactin-antagonist domain characterized by a single amino acid substitution at the position corresponding to 129 of the human prolactin protein, wherein said amino acid substitution is a glycine to an arginine.
Dependencies are inferred from the claim text.